Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Economy & Forex

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Permira buys German specialty pharma group Neuraxpharm

share with twitter share with LinkedIn share with facebook
09/22/2020 | 01:26pm EDT

Buyout group Permira has agreed to buy German pharma group Neuraxpharm, seeking to gain from an expected rise in demand for the company's antidepressants, painkillers and other products for the central nervous system, the companies said on Tuesday.

The deal values the company at almost 1.7 billion euros (1.46 billion pounds), including debt, or at about 13 times its expected 2021 core earnings, three people close to the matter said.

Permira and the seller, private equity firm Apax, declined to comment on the financial details of the deal.

The British buyout firm prevailed against competing offers from Carlyle, ICG and Goldman Sach's private equity arm, the sources said.

The runners-up also declined to comment.

Apax bought Neuraxpharm in 2016, combined it with Invent Farma, and later strengthened the company through add-on acquisitions, such as FB Health and Farmax.

The company makes specialty pharmaceuticals for neurological and psychiatric disorders, including epilepsy, Parkinson's disease, Alzheimer's disease, depression and psychosis. It has annual revenues of more than 460 million euros and 850 employees.

While global M&A activity hit its lowest level in more than a decade in the second quarter, deal-making in the healthcare sector is expected to buck the trend this year as its products and services are considered resilient to the COVID-19 crisis, investment bankers say.

Jefferies advised Apax on the deal, which Reuters flagged in July, while Rothschild advised Permira.

Jefferies is supplying a pre-arranged financing package - so-called staple financing - of more than 6.5 times core earnings, a source close to the matter said.

Apax Global Alpha, which is an investor in the Apax VIII fund selling Neuraxpharm, said the deal is expected to result in a gross multiple on invested capital of 3.5 times and a gross internal rate of return of 36%.

($1 = 0.8517 euros)

By Arno Schuetze


Stocks mentioned in the article
ChangeLast1st jan.
ROTHSCHILD & CO -2.95% 23 Real-time Quote.-10.16%
THE CARLYLE GROUP INC. -1.83% 25.77 Delayed Quote.-19.67%
share with twitter share with LinkedIn share with facebook
Latest news "Economy & Forex"
02:39aOil rises 2% on U.S. Gulf shutdowns, outlook weak
RE
02:37aJapan PM Suga to announce plan for fresh stimulus package to ease pandemic pain
RE
02:34aChina's domestic jet fuel demand back to near pre-COVID levels
RE
02:30aWALL STREET STOCK EXCHANGE : Asian shares, U.S. stock futures sag on coronavirus, U.S. election worries
RE
02:26aItaly's antitrust probes Google for possible abuse of dominant position
RE
02:25aMalaysia's Sept exports rise 13.6%, fastest in nearly two years
RE
02:23aSomalia's economy to contract 2.5% this year, World Bank says
RE
02:23aChina eyes launch of national emissions trade scheme within five years
RE
02:22aCar insurance startup Root raises $724.4 million in IPO
RE
02:19aVisa's deal to buy fintech startup Plaid faces antitrust scrutiny
RE
Latest news "Economy & Forex"